Archive for the ‘Infringement’ Category

Akami/McKesson Decision Re-defines Induced Infringement

Monday, September 10th, 2012

In a 6-5 decision, the Fed. Cir., sitting en banc, decided two appeals which presented questions closely related to when an actor is liable for inducing infringement under 271(b); Akami Technologies, Inc. v. Limelight Networks, Inc. and McKesson Tech’s., Inc. v. Epic Systems Corp., App. No. 2010-1291 (Fed. Cir. August 31, 2012).

The claims at issue were both multi-step method claims.  McKesson’s patent claimed a software application that it argued Epic indirectly infringed when it caused patients to initiate communications providing “My Chart” healthcare information to which the providers would respond. Epic did not perform any of the claimed steps. I won’t discuss the Akami facts, since they are less closely related to life sciences.

The court framed the question as limited to the type of infringing acts that would impart liability for induced infringement under 271 (b) and did not purport to redefine direct infringement under 271(a). The court framed the questions to be resolved as:

“[W]hether a defendant may be held liable for induced infringement if the defendant has performed some of the steps of the claimed method and has induced other parties to commit the remaining steps [as in Akami], or if the defendant has induced other parties to collectively perform all of the steps of the claimed method, but no single party has performed all of the steps itself [as in McKesson].”

(more…)

Infringement by Unobvious Changes – A Look (Way) Back

Sunday, October 16th, 2011

As a much younger attorney, I gave a presentation at the 1990 AIPLA Annual Meeting:  “A Review of Recent Federal Circuit Decisions Relating to Infringement” (AIPLA Selected Legal Papers, 9, 3 (July 1991)), in which I wrestled with the question of whether or not a novel and unobvious chemical composition would infringe under the doctrine of equivalents.  Since this is the central issue that the Supreme Court will be asked to resolve in Saint-Gobain Ceramics v. Siemens Med. Sol’ns, Supreme Ct. No. 11-301, I thought these excerpts might be of interest:

* * *

“Although no recent case (or any case) was found where the unobviousness of a substituted ingredient led to a holding of non-infringement of an accused composition that otherwise met the tripartite test, such a holding would be appropriate.  At the very least, Atlas Powder Co. v. DuPont DeNemours & Co., 750 F.2d 1569 (Fed. Cir. 1985), suggests that an unexpected result achieved by the accused composition would support a finding of non-interchangeability [and thus, noninfringement].

(more…)

Inducement of Patent Infringement: Even Without Knowledge of the Patent?

Friday, October 15th, 2010

Under 35 U.S.C. § 271(b) “[w]hoever actively induces infringement of a patent shall be liable as an infringer.”  On October 12th, the Supreme Court has granted certiorari (link below) for the case of Global-Tech v. SEB (S. Ct. No. 10-6) to determine whether “deliberate indifference of a known risk” that infringement may occur satisfies the state-of-mind element of a claim for actively inducing infringement.  Traditionally, the standard has been that the alleged inducer “knew of the patent” as held by DSU Medical Corp. v. JMS Co., Ltd., 471 F.3d 1293 (Fed. Cir. 2006) (en banc).  However, this standard was recently eroded by SEB (T-Fal) v. Montgomery Ward & Co., 594 F.3d 1360 (Fed. Cir. 2010), in which the Federal Circuit held that a subjective “deliberate indifference” to potential patent rights is sufficient, while comparing and disregarding a more objective “should-have-known” standard.  The petition for cert. was supported by an amicus brief co-signed by a number of influential professors, who argued that the inconsistencies should be resolved.

But without actual knowledge being required, no matter whether the standard is an objective test or a more subjective one that attempts to take into account the state of mind of the alleged inducer(s), it is easier to make a claim for inducement of infringement.  Under this standard, to avoid being vulnerable to a claim, companies need to take greater precautions to carefully survey the patent landscape in which they do business, and will be forced to have greater respect for patent rights.  As the Supreme Court approaches settling the question of what is required to satisfy the state-of-mind element of inducement, overarchingly it will be contemplating policies of the enforceability of patents, which is directly associated with the overall value of patents to their owners and licensees.

–Note by Nicholas P. Lanzatella, Schwegman, Lundberg & Woessner.

SEBAmicusPetition-1

Should Preambles “Count” – The Debate Continues

Tuesday, October 12th, 2010

On September 13th, the Fed. Cir. reversed a summary determination of non-infringement which turned on the question of whether or not to give weight to a term that appeared only in the preamble of a claim to a prostate treatment involving laser ablation. American Med. Systems, Inc. and Laserscope v. Biolitec, Inc., 2009-1323 (Fed. Cir. Sept. 13, 2010) (link at the bottom of post). The district court found that the recitation that the method was one for “photoselective vaporization of tissue” in the preamble effectively limited the claim to wavelengths of light that were highly absorbed by tissue but not by the water used in the procedure. The infringer was using a higher wavelength, and the district court found that this did not meet the “photoselective vaporization” limitation.

The majority of the Fed. Cir. panel disagreed, stating that “most importantly, the descriptor ‘photoselective’ does not embody an essential component of the invention… [but] is simply a descriptive name for the invention that is fully set forth in the bodies of the claims… nothing in the claim language suggests that the term ‘photoselective’ further limits [the wavelengths recited in the apparatus claims].” The panel referred to “photoselective vaporization” as a “label for the overall invention, and not a limitation on the claims.” The majority found that the denigration of the prior art “does not rise to the level of a disclaimer of wavelengths [disclosed to be preferable by patentee].”

In a vigorous dissent, Judge Dyk noted: “Over the years our court has struggled to make sense of when a preamble should be construed as limiting…[and] we have not succeeded in articulating a clear and simple rule…. It seems to me that a rule recognizing that all preambles are limiting would make better sense and would better serve the interests of all concerned.” On the facts, Judge Dyk would have found the term in question limiting, if only on the basis that patentee committed “patent profanity” (as Tom Irving has referred to it) by including statements in the specification that “the wavelength used according to the present invention for BPH treatment [accomplishes photoselective vaporization].” Judge Dyk noted that “we have repeatedly held that the use of words ‘the present invention’ can be read to limit the invention to what is described as such…. by adding this terminology [in a CIP] during the prosecution of the ‘764 patent, the patentee conceded that the term gave life, meaning and vitality to the claims.”

This somewhat sarcastic reference to the oft-quoted and nearly poetic legal standard from Pitney Bowes (or is it older?) aside, a global rule that preambles always are claim limitations would conflict with the maxim that statements of intended use in preambles (or anywhere else) are not limiting. A rule that they are limitations would convert all those claims that begin: “A composition for treating condition x comprising ingredients a, b and c “ into process claims. On second thought, since there are a scattering of decisions finding that statements of intended use in preambles ARE limiting (see In re Watanabe, 315 F.2d 924), maybe it is time for patent prep/pros folks to simply STOP WRITING PREAMBLES.

At the very least, a take-away from this decision should be that anything you put in a preamble should be tested to see if it should either be put into the body of the claim or be tossed. For now, I think that the best articulation of the standard is in, inter alia, Eaton Corp. v. Rockwell Internat’l Corp., 01-1633 (Fed. Cir. 2007): “When limitations in the body of the claim rely upon and derive antecedent basis from the preamble, then the preamble may act as a necessary component of the claimed invention.” This is pretty close to a requirement for a finding of specific intent by the drafter to use the preamble as a limitation.

09-1323 09-13-10